IPru Life posted a 7% YoY growth on overall APE and 6% on individual APE, a first positive growth in 13 months. On FYTD21 new business de-grew -27% and is likely to end in negative growth for second consecutive year. IPru Life...

Long-term product strategy key to margin improvement Max Life reported individual APE growth of 21% YoY (up 11% YoY in 9MFY21). The strong growth came on the back of traction in non-par savings and protection products. Individual protection sales are up 54% YoY in 9MFY21. Number of individual protection policies sold during 9MFY21 is up 29% YoY at 164,000 (FY20: 183,000). Overall protection APE is up 39% YoY during 9MFY21 (group up 21% YoY). Growth in the individual protection segment has been led not just by volume growth but price increase as well. For 9MFY21, the case size has increased by ~Rs3000 to Rs20,000. The share of individual protection has now increased by ~200bps YoY to 10% for 9MFY21 while overall protection...

Growth momentum reviving in the proprietary channel MAX Life Insurance (MAXLIFE) has demonstrated a resilient performance amid a challenging macro environment, with 21% APE growth, led by robust growth in Non-PAR savings and a recovery in ULIP. After witnessing robust Protection growth over 1HFY21, the same has moderated during 3Q. Shareholders' PAT grew at 43% YoY during 3QFY21. Absolute VNB growth stood robust (65% YoY), led by a VNB margin of 28.6%. This has been supported by robust trends in Non-PAR savings and...

Traditionally a Par player, MAXLIFE has significantly diversified its product mix and has made significant strides to capture the protection and non-par segment. MAXF has been able to build a strong franchise with a profitable agency channel. AXIS bank transaction will also give more comfort to the renewal on the bancassurance tie-up which is due to expire in September 2021. MAXF has already delivered strong growth thus far and we believe stock price largely reflects the positives from the AXIS deal as well as top-line growth. As most positives are already...

Value of New Business (VNB) written during H1FY21 grew by 20% y-o-y, while New Business Margin (NBM) expanded by 320 bps y-o-y to 24.2%, helped by a shift in product mix towards NPAR- Savings and Protection products. EV was at Rs 11,047 Cr., with RoEV at 17.5%. We believe the Indian insurance sector has a long growth runway; and Max Life, with strong metrics, stable bancassurance partnership with Axis Bank, etc is well-placed to benefit from growth opportunities. Max Financial is available a reasonable valuation of 1.7x / 1.5x FY2022E / FY2023E MCap / EV; We maintain Buy with a revised PT of Rs. 750....

Max Life reported individual APE of Rs11.44bn for 2QFY21, growing by 10% YoY. During 1HFY21, individual APE was up 5% YoY. Renewals have been healthy, growing by 22% YoY. Growth during 1HFY21 was driven by non-par savings and protection. The share of non-par savings increased to 31% as of 1HFY21 compared to 20% in 1HFY20 while protection share (individual + group) stood at 20% compared to 14% last year. In the near term, we expect growth in the linked savings space to remain weak. From a product strategy standpoint, the management's current focus is to push more of protection and non-par savings. Besides supporting growth, these segments are also highly profitable and will thereby help improve the headline profit margin. VNB margin in 1HFY21 stood at...

Max Financial Services' (MFS') deal with Axis Bank appears to be progressing positively, even though the lender will now buy a lower stake in Max Life Insurance Co. Ltd. (MLIC). Mutually altering the deal, Axis Bank now will acquire 17% in MLIC to increase its holding to 18% (lower than a 29% stake buy announced earlier). The companies have executed a definitive agreement to the effect but are yet to approach regulatory authorities with the revised applications. Axis Bank is one of the key bancassurance partners for Max Life, contributing ~57% (as...

We expect an FY21-23E APE/VNB CAGR of 12.6/16.2%. We retain our ADD rating with an unchanged target price of Rs 645 (FY21E EV + 21.3x FY22E VNB). Despite a difficult environment, MAXL delivered an APE decline of just 3.5% YoY. The margin was 250bps YoY lower mainly due to an increase in reinsurance costs, which the company has passed on 2QFY20 onwards. We expect the margin to improve hereon. We believe the deal with AXSB will provide long-term distribution capability.

Margin contraction due to cost over-runs and low rates Max Life reported APE of Rs6.6bn for the quarter, down 4% YoY. Understandably, new business generation was affected during the quarter due to the lockdown. Renewals growth was 6% YoY. Persistency ratios have dipped across cohorts. In the last earnings call, the management had highlighted that April '20 saw some stress in terms of renewals collections due to grace period granted in light of the covid situation. We would keenly watch persistency ratios from here onwards. In the near-to-medium term, growth in the savings segment is expected to remain weak. Therefore, the management's focus would be on pushing more of protection and non-par...

Max Life's overall APE de-grew 4% YoY supported by decent growth in single & regular premiums. Protection segment remains the key focus with shift of Product mix to NPar savings and Protection as Par share is reduced. Margins disappointed and fell to 17% for 1Q21 despite of favorable product mix on account of lower interest rates and higher cost overruns. Approvals with respect to Axis/Max/MSI deal should not get into hurdle post queries from IRDAI/RBI but should take time. We retain HOLD with revised TP of Rs545...

We believe demand will likely be driven by NPAR (savings and protection) in the near term and then move to PAR as risk appetite returns. We believe demand for ULIPs is still some time away. Increased interest in term and health products. Google trends indicate a steep rise in interest for term and health insurance to near all-time high levels. We also observe increased interest in HDFC Life and SBI Life as companies. Search for ULIPs has decreased significantly, most likely due to subdued markets and customers' desire for stability and assured returns.

Valuation and view. A strategic JV partner such as AXSB provides long term distribution capability, ending uncertainty and market anxiety over the future of the AXSB distribution arrangement. We expect MAXL to lower its dependence on proprietary channels which will be VNBM accretive as investments in channels reduce. We have increased our VNB estimates for FY20/21E by 18.4/15.6%, and fine tuned our DCF assumptions, resulting in a 10.7% increase in TP to Rs 620. Key risks: Lower growth, higher cost over-runs, supply overhang due to promoter pledges, and any hurdles in deal. MAXLs 4QFY20 APE declined 15.1% YoY (better than expected!) to Rs 15.1bn as lock-down impacted sales in Mar-20. Total VNB for FY20 grew 4.8% YoY to Rs 9.0bn as margins declined 10bps YoY to 21.6%. We maintain our BUY rating with TP of Rs 620.

Focus on maintaining absolute VNB in FY21 amid sales downturn Max Life reported NBP of Rs18.9bn for the quarter (5% below our estimate), down 8.3% YoY. Understandably, new business generation was affected due to the lockdown in the latter half of Mar'20. We think that renewal growth was comparably better than ICICI Pru Life and HDFC Life at 15.1% YoY. However, there was some deterioration in persistency ratios in the ULIP segment on account of volatile capital markets. April'20 also saw some stress in terms of renewals collections on the back of grace period in light of the covid situation. Normalcy is expected to return by June'20. In the near-to-medium term, growth in the savings segment is expected to...

Max Financial Services (MFS) posted modest numbers for Q4FY2020,with below expectations operating performance, and posted slower business growth in Value of New Business (VNB) and Annualised Premium Equivalent (APE) due to impaired collections because of the lockdown. The life insurance business, Max Life Insurance (MLIC, MFS has 72.5% shareholding) saw gross written premium (GWP) rise by 6% y-o-y, despite the lockdown, which impacted the last part of March, which typically is a seasonally important period for life insurance players. The 13th-month...

Max Life's overall APE grew 5% YoY supported by decent growth in single & regular premiums. Protection segment remains the key focus with shift of Product mix to NPar savings continuing. Margins remained stable YoY at 21.6% for FY20 (but improved sequentially to 22.8% in 4Q20) on account of support from NPar growth. Persistency has improved across all buckets except the 61m persistency (upto Mar'20 i.e.11m) being affected by the ULIP segment. We retain BUY with revised TP of Rs518 (Rs610) valuing Max Life based on 2.3x Mar-22 EV (from 2.6x Sep-22 EV), we reduce Holdco discount...

Valuation and view. A strategic JV partner such as AXSB provides long term distribution capability, ending uncertainty and market anxiety over the future of the current AXSB partnership arrangement. We expect MAXL to lower its dependence on proprietary channels which will be VNBM accretive as investments in channels reduce. We rate MAXF a BUY with an increased TP of Rs 560 (MAXL: Mar-21E EV + 25.0x FY22E VNB). We have not changed our estimates but we remove the 22% discount to VNB, reduce holding company discount to 10%, build in a 10x multiple to annual leakage at MAXF, and lastly we adjust our cost of capital downward to reflect lower rates. Key risks: higher cost over-runs, supply overhang due to promoter pledges, and non completion of deal. JV with AXSB provides long term distribution capability to the business and ends uncertainty and market anxiety on the future of the current partnership. We expect dependence and hence investments in proprietary channels to reduce, thereby increasing VNB. We rate MAXF a BUY with an increased TP of Rs 560 (Mar-21E EV + 25.0x FY22E VNB).

Max Financial announced a 29% stake acquisition by Axis Bank in Max Life Insurance yesterday for Rs16bn (link). The deal announcement comes on the back of Axis Bank and Max Financial entering into exclusive talks to explore a long-term strategic distribution partnership some time ago. Despite delivering comparable margins and profitability, Max Life's valuation has always been a few notches below comparable peers. A major overhang on the stock has been lack of permanency on the distribution front. The distribution arrangement with Axis Bank, which accounts for 55% of the business, was due for renewal in Sep'21. With this deal, we believe these concerns stand largely addressed. The transaction would bring together 3rd...

Max Financial Services Limited (MFS) announced that it had signed definitive agreements with Axis Bank Limited (Axis Bank) where the companies will be joint venture partners in Max Life Insurance Company Ltd (MLI). As per the agreement, Axis Bank will hold a 30% stake in Max Life once the deal is finalized in 12-18 months (expected), pending regulatory approvals. Due to the cap on the stake that a bank may hold in a life insurance company, Axis Bank stake is likely to remain at 30% in the JV. However, shareholders of MFS...

Max Life's total exposure to Yes Bank is ~Rs20bn in the form of tier 2 bonds, out of which ~Rs10bn is at the shareholder level. The balance ~Rs10bn is divided equally at the policyholder level between ULIP and par (Rs5bn each). In the worst case scenario, under which a complete write-off of the shareholders exposure is taken, the impact on EV would be 10%. The management is of the opinion that it is unlikely to face any haircuts on the tier 2 bonds exposure at the shareholder level since it has never happened in the history of Indian banking M&A;/restructuring. Note that the tier 2 bond exposure enjoys a cushion of ~Rs360bn (Rs270bn equity, Rs90bn tier 1 bonds). While...

With a new indiv. tax code and Axis Bank embracing open architecture we expect business growth momentum to slow down in FY21-22E. Additionally, we continue to watch out for the renewal of partnership with Axis Bank. We rate MAXF a BUY with an changed TP of Rs 560 (MAXL: Dec-20E EV + 18.8x FY22E VNB). We use a holding company discount of 30%, continue with a 22% discount on VNB for Axis Bank deal, and a 10x multiple to annual leakage at the holding co level. Key risks include lower growth, higher cost over-runs, and supply overhang as a result of promoter pledges. MAXL reported in-line nos with total APE growing 16.0% YoY and 9MFY20 VNB margin was at 21.0% (+60bps YoY)- high costs continue to weigh on margins. We maintain our BUY with TP of Rs 560.